Study of the Effect of A366 (A G9a Methyltransferase Inhibitor) on Osteogenic Potential of Rat Bone Marrow-Derived Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are multipotent stem cells that have potential to differentiate into connective tissue lineages. They also have special properties such as immunomodulation and secretion of growth factors. Histone methyltransferase G9a is one of the factors that control stem cells behaviors and features. Hence, it is important to study the role of G9a in MSCs biological behaviors and potentials. MSCs were isolated from rat bone marrow and cultured in vitro. Then, the expression of positive markers (CD90 and CD 73) and negative markers (CD45) were analyzed using flowcytometry. BM-MSCs were treated with different doses of A366, and then were differentiated to osteocyte. Osteogenesis were analyzed using oil red staining and real time-PCR. BM-MSCs were expanded as adherent cells with fibroblastic morphology. More than 85% of cells were positive for CD73 and CD90, and negative for CD45. The treatment of BM-MSCs with A366 reduced osteogenesis as evaluated by oil red staining and gene expression analysis. A366, as an epigenetic regulator decreases the osteogenic potential of BM-MSCs. Use of these regulators for cancer therapy, might influence tissue regeneration and homeostasis.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.